glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results Long-term of in obesity and cardiovascular disease in the SELECT Effects of semaglutide with and

2010 Nov;38(11):2199-206

Lixisenatide vs

& Pyke, C

Effect of bariatric surgery on disease outcomes in patients with inflammatory bowel disease: a US-based propensity matched cohort study

Sometimes searched as "compound tirzepatide" or "tirzepatide compound," it is the same medication prepared for an individual patient by prescription

We are going to be talking about the kidney endpoints of the FLOW trial in some detail and the cardiovascular endpoints as well. The First Dedicated Kidney Outcome Trial with a GLP-1 Receptor Agonist Once-Weekly Semaglutide and the FLOW Trial Results will take place on Monday, June 24, from 1:30 p.m